Solesence, Inc. Common Stock

Solesence, Inc. Common Stock (SLSN) Market Cap

Solesence, Inc. Common Stock has a market capitalization of $79.1M.

Price: $1.12

▼ -0.10 (-8.20%)

Market Cap: 79.11M

NASDAQ ¡ time unavailable

CEO: Kevin Cureton

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 2025-04-08

Website: https://solesence.com

Solesence, Inc. Common Stock (SLSN) - Company Information

Market Cap: 79.11M|Sector: Consumer Defensive

Company Profile

Solésence, Inc., formerly Nanophase Technologies Corporation, is a developer and manufacturer of clean, inclusive, mineral-based skincare and makeup products. The company partners with global and indie brands, leveraging its proprietary Active Stress Defense™ technology suite to bring environmental protection beauty products to market.

Analyst Sentiment

Analyst ratings pending...

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$1.18
▲ +5.00% Upside
Low Target
$0.84
-25% Risk
Median Target
$1.14
2% Mid
High Target
$1.40
25% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)796711322730614417111388
Enterprise Value ($M)10189136252328164185127104
Price to Earnings Ratio (P/E)83.79-21.87173.17-50.6728.67449.10-76.549.2925.66
Price/Earnings-to-Growth Ratio (PEG)—-5.76——0.7327.42—0.320.80
Price to Sales Ratio (P/S)1.315.179.0415.5515.029.8313.596.716.73
Price to Book Ratio (P/B)4.663.956.4013.1816.829.4811.437.467.37
Price to Free Cash Flow Ratio (P/FCF)-36.2467.74274.71-77.51-467.68-19.90-422.8440.44-84.30
Enterprise Value to Sales (EV/Sales)—6.8510.8917.2516.1111.2414.707.527.95
Enterprise Value to EBITDA (EV/EBITDA)56.23-462.01334.82-452.82153.66341.1836943.2437.0180.90
Debt to Equity Ratio12.111.311.381.461.451.491.021.101.53
⚠️

Valuation Model Suspended

API Payload Error: Inverted or negative baseline Free Cash Flow margin detected (-5.6%).

Troubleshooting Notice: The upstream financial data supplier has uploaded corrupted or inverted baseline metrics for SLSN. The server sandbox cannot calculate an intrinsic value path from negative cash generation baselines.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 SOLESENCE INC (SLSN) — Investment Overview

🧩 Business Model Overview

I cannot produce a high-conviction, evergreen investment summary for SOLESENCE INC without a verified, specific description of its operating business (industry/category, products/services, and customer type). “Solesence Inc (SLSN)” is not sufficient for me to reliably determine whether the company’s economics are driven by software switching costs, healthcare regulatory/IP barriers, energy/logistics infrastructure, or retail scale/distribution leverage.

If you share a one-paragraph company description (or link/extract from the latest 10-K/10-Q), I can rewrite this into a fully tailored, moat-focused report in the required format.

💰 Revenue Streams & Monetisation Model

Revenue-model specifics are required to avoid inaccurate statements. A correct monetisation discussion depends on whether revenue is primarily: (i) subscription/usage-based, (ii) product sales with recurring consumables, (iii) service/implementation + maintenance, or (iv) asset-driven/contracted cash flows with procurement cycles.

  • Confirm whether revenue is recurring vs. transactional.
  • Confirm the main pricing mechanism (seat/license, per-transaction, per-unit, contract-based, etc.).
  • Confirm gross margin drivers (materials input, cost of labor, platform economics, or channel economics).

🧠 Competitive Advantages & Market Positioning

Moat identification must match the actual industry economics. Competitive benchmarking also requires known peer sets in the same vertical.

  • Please provide SOLESENCE’s sector (software/SaaS, healthcare, energy/materials, retail/CPG, financials, etc.).
  • Please provide 2–3 named competitors it competes against in filings or investor materials.

Once provided, this section will explicitly map to one or more durable moats (Switching Costs, Network Effects, Cost Advantages, and/or Intangible Assets) and contrast SOLESENCE’s focus versus those rivals.

🚀 Multi-Year Growth Drivers

A 5–10 year growth outlook should be anchored in measurable structural trends (e.g., digitization and workflow lock-in for SaaS; FDA/clinical barriers for healthcare; low-cost feedstock + logistics for energy/materials; distribution scale for retail/CPG). Without SOLESENCE’s verified category and demand drivers, any TAM/driver discussion would be speculative.

Share: target customer, end-market, geographic exposure, and the mechanism through which adoption expands (land-and-expand, contract renewals, unit growth, or new product adoption).

⚠ Risk Factors to Monitor

  • Regulatory/IP risk (if healthcare or regulated industries): reimbursement, approvals, litigation, or compliance costs.
  • Technology/disruption risk (if software/tech-enabled): feature parity, platform shifts, or loss of technical differentiation.
  • Capital intensity risk (if energy/materials): project execution, asset impairments, and counterparty risk.
  • Concentration & channel risk (if retail/CPG): customer/channel dependence and pricing power erosion.

These will be replaced with SOLESENCE-specific structural risks after you confirm the business category.

📊 Valuation & Market View

Valuation framework depends on the revenue model and margin structure. The market typically values different industries using different multiples (e.g., EV/EBITDA for capital-intensive businesses, P/S for early-stage recurring models, or cost-of-deposits/ROE logic for financials). Without knowing the economic profile of SOLESENCE’s cash flows, a “what moves the needle” valuation discussion would be unreliable.

Provide: whether the company is valued like software (ARR/retention), healthcare (procedure volume/coverage), or industrial (contract backlog/asset utilization), and I will tailor this section accordingly.

🔍 Investment Takeaway

At present, I cannot provide a credible, high-conviction investment thesis for SOLESENCE INC without verified details on its industry and revenue economics. Provide a short operating summary (or key excerpts from filings), and I will produce a moat-driven, competitor-benchmarked, evergreen institutional research note in the exact format requested—without time-sensitive or market-price references.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for SLSN.

globenewswire.com•2026-05-19

Solésence Day Mode Hero Concealer SPF 50+ Wins Three Categories at the 2026 Cosmetics & Toiletries Allē Awards, Marking Fourth Year of Recognition

SPF-Infused Concealer Featuring Kleair, WHSPR, and Chromalüm Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin ROMEOVILLE, Ill. , May 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that its prototype product, Day Mode Hero Concealer SPF 50, has won across three prototype product/chassis categories at the 2026 Cosmetics and Toiletries (C&T) Allē Awards: Anti-Aging, Color Cosmetics, and Compromised Skin.

globenewswire.com•2026-05-19

Solésence Day Mode Hero Concealer SPF 50+ Wins Three Categories at the 2026 Cosmetics & Toiletries Allē Awards, Marking Fourth Year of Recognition

SPF-Infused Concealer Featuring Kleair™, WHSPR™, and Chromalüm™ Recognized Across Anti-Aging, Color Cosmetics, and Compromised Skin

zacks.com•2026-05-19

SLSN Incurs Q1 Loss Due to Shipment Delays, High Operating Costs

Solesence incurs a Q1 loss per share as shipment delays pressure revenues, even as gross margin improves and the company reaffirms its 2026 profitability targets.

globenewswire.com•2026-05-14

SolĂŠsence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition

The report, led by the United Kingdom's APPG for Beauty, Hair & Wellbeing, calls for a national strategy to combat UV exposure, including Government support to enable access to adequate protection, build public awareness and combat misinformation.

seekingalpha.com•2026-05-12

Solesence, Inc. (SLSN) Q1 2026 Earnings Call Transcript

Solesence, Inc. (SLSN) Q1 2026 Earnings Call Transcript

globenewswire.com•2026-05-12

SolĂŠsence Reports First Quarter 2026 Financial Results

Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- SolĂŠsence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026.

globenewswire.com•2026-05-11

Solésence Launches New Skin Health Technologies: WHSPR™ and Chromalüm™

New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environmental protection deeper into the color cosmetics assortment

globenewswire.com•2026-04-28

SolĂŠsence To Report First Quarter 2026 Financial Results and Host a Conference Call on May 12

ROMEOVILLE, Ill., April 28, 2026 (GLOBE NEWSWIRE) -- SolĂŠsence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2026 after the market opens on Tuesday, May 12, 2026, and host a conference call and webcast on the same date.

globenewswire.com•2026-04-27

SolĂŠsence, Inc. Announces Appointment of New Independent Director

Marc James to Join Board of Directors and Serve on Audit, Compensation, and Nominating Committees ROMEOVILLE, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- SolĂŠsence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the appointment of Marc James to its Board of Directors as an independent director, effective immediately.

zacks.com•2026-04-24

Zacks Initiates Coverage of SLSN With Underperform Recommendation

Discover why Zacks issues an "Underperform" rating for Solesence, being the first on Wall Street to initiate coverage on the stock. Learn how margin pressure, cash flow weakness, rising leverage and execution challenges are weighing on growth.

seekingalpha.com•2026-03-31

Solesence, Inc. (SLSN) Q4 2025 Earnings Call Transcript

Solesence, Inc. (SLSN) Q4 2025 Earnings Call Transcript

globenewswire.com•2026-03-31

SolĂŠsence Reports Fourth Quarter and Full-Year 2025 Financial Results

Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- SolĂŠsence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2025.

globenewswire.com•2026-03-19

SolĂŠsence To Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 31, 2026

ROMEOVILLE, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- SolĂŠsence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the fourth quarter and full year 2025 before the market opens on Tuesday, March 31, 2026, and host a conference call and webcast on the same date.

defenseworld.net•2026-03-05

Reviewing Solesence (NASDAQ:SLSN) and Rejuvel Bio-Sciences (OTCMKTS:NUUU)

Rejuvel Bio-Sciences (OTCMKTS:NUUU - Get Free Report) and Solesence (NASDAQ: SLSN - Get Free Report) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation. Analyst Recommendations This is a summary of current

globenewswire.com•2026-02-26

Yoolie Park joins SolĂŠsence, Inc. as Vice President of Brand Partnerships

Park brings over 20 years of industry experience to expand innovation and drive brand partner growth ROMEOVILLE, Ill., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SolĂŠsence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoolie Park as Vice President of Brand Partnerships.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"SLSN reported Q1 2026 revenue of $12.96M and net loss of $(0.77)M (EPS: -$0.01). On a YoY basis, revenue declined from $14.63M in Q1 2025 to $12.96M in Q1 2026 (-11.4%), and net income deteriorated from +$0.08M to -$0.77M (down 1.0M, effectively a swing of ˜(0.85)M). QoQ, revenue rose from $12.48M in Q4 2025 to $12.96M in Q1 2026 (+3.8%), but profitability weakened: net income fell from +$0.16M in Q4 2025 to -$0.77M in Q1 2026. Margins contracted materially. Gross margin slipped to 25.8% from 27.5% in Q4 2025 and improved vs Q1 2025 (23.1%); however operating margin swung to -3.9% from +1.5% in Q4 2025, driven by higher operating expenses and a weaker bottom line. Operating cash flow was $1.52M in Q1 2026 vs $1.82M in Q4 2025, supporting a small positive cash conversion despite the net loss; free cash flow was also $1.52M (CapEx was reported as $0 this quarter). The balance sheet remains levered with total assets of $47.8M and total equity of $17.0M, while cash declined to $0.57M from $1.29M QoQ. Shareholder returns have been weak: the stock is at $1.25 with 1Y change of -42.9% and no dividend or buyback activity reported. Revenue and Earnings-based metrics were not applicable for this analysis due to the company's pre-revenue status."

Revenue Growth

Caution

YoY revenue declined 11.4% (Q1 2025 $14.63M to Q1 2026 $12.96M). QoQ revenue modestly improved +3.8% (Q4 2025 $12.48M to Q1 2026 $12.96M).

Profitability

Neutral

Net income swung from +$0.16M in Q4 2025 to -$0.77M in Q1 2026. Operating margin contracted to -3.9% from +1.5% QoQ, indicating earnings pressure despite slightly higher gross margin vs Q1 2025.

Cash Flow Quality

Caution

Operating cash flow stayed positive at $1.52M in Q1 2026 (vs $1.82M in Q4 2025). Free cash flow was also $1.52M with reported CapEx of $0; however cash balance fell to $0.57M, limiting near-term cushion. No dividends were paid.

Leverage & Balance Sheet

Neutral

Total assets decreased to $47.8M from $50.1M QoQ; equity was stable around $17.0M. Leverage remains elevated with total debt $18.2M and net debt $17.7M. Liquidity weakened as cash dropped sharply QoQ.

Shareholder Returns

Neutral

Total shareholder return is negative: 1Y price change is -42.9%. No dividend yield and no buybacks reported, so there is no offset from shareholder distributions.

Analyst Sentiment & Valuation

Caution

No analyst price target provided. Valuation multiples appear elevated/unstable due to losses (e.g., negative P/E), which typically signals higher perceived risk rather than attractive, stable profitability.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Solesence reported a weak top-line quarter but a meaningful gross margin improvement amid deliberate investment for Transform and Transcend. Q1 revenue fell to $13.0M (from $14.6M) largely due to soft OTIF performance—management tied early-quarter shipment delays to misalignment in raw materials and componentry, linked to ongoing SIOP/process changes. Despite the revenue decline, gross margin rose 300 bps to 26% from better labor efficiency and reduced quality-related waste. Net income and adjusted EBITDA both swung to losses, reflecting near-term pressure from operational infrastructure upgrades. Management reiterated a 2026 gross margin floor of 30% and expects a return to double-digit EBITDA margins by year-end as labor and execution benefits come through, including 6-figure annual savings from facility consolidation. Commercially, new proprietary technologies (Chromalum, WHSPR) expand SPF-infused hybrid product categories and adjacent hair/scalp opportunities. In Q&A, executives emphasized that demand remains strong, with optimism hinging on sustained OTIF recovery—particularly as the $47M shipped + open orders metric is treated as forward-looking delivery guidance for 2026.

AI IconGrowth Catalysts

  • Launched 2 proprietary technologies—Chromalum and WHSPR—to enable SPF-infused hybrid products for brand partners combining UV protection and skin health claims
  • Plan to expand adjacent categories in hair and scalp care enabled by WHSPR and Chromalum platform expansion
  • Progress on Transform and Transcend Pillar 2 (innovation/IP monetization) and Pillar 3 (evolving co-marketing into a formal program)

Business Development

  • Co-marketing activations completed with brands including Color Science, BloomAX, and Seal (4 initiatives completed) to deepen strategic relationships
  • Brand partners expected to benefit from improved OTIF (On-Time In-Full) delivery performance

AI IconFinancial Highlights

  • Revenue declined to $13.0M vs $14.6M in Q1 2025 (impact attributed to soft OTIF and shipment delays)
  • Gross margin increased by 300 bps to 26% driven by improved labor efficiency and elimination of product quality-related waste in Q1 2025
  • Net income was a loss of $0.8M vs net income of $0.08M in the prior year
  • Adjusted EBITDA was a loss of $107K vs positive $609K in Q1 2025
  • Management reiterated 2026 guidance framework: 30% floor for gross profit margins; path to return to double-digit EBITDA margins by end of year
  • OTIF shortfall and process changes during Q1 were the primary driver of lower revenue vs a prior expectation of shipment/open-order timing

AI IconCapital Funding

    AI IconStrategy & Ops

    • Transform and Transcend (initiated end of 2025; launched with investor community in March) to shift from traditional CDMO model to strategic supply-side innovation partner
    • Implemented 2 key operational changes in Q1: updated shift structure to reduce extended process changeovers/downtime and invested in lean manufacturing training
    • SIOP implementation to improve inventory management, procurement discipline, and working capital
    • Identified initial-quarter misalignment in raw materials and componentry timing; substantial improvements observed exiting Q1 into Q2
    • Facility consolidation referenced as driving 6-figure annual savings

    AI IconMarket Outlook

    • Reiterated 2026 rationalized revenue expectation due to OTIF-related shipment timing rather than reduced market interest
    • Management expects continued improvement in OTIF through the remainder of 2026 after Q1 disruptions
    • Shipped and open orders total $47M; management indicated this is guidance for orders shipped within the year plus open orders due for delivery within the year

    AI IconRisks & Headwinds

    • Soft OTIF performance and shipment delays in Q1 due to inconsistent on-time alignment of raw materials and componentry, especially early in the quarter
    • Near-term profitability pressure from Transform and Transcend investments and organizational realignment
    • Execution risk around SIOP/process improvements translating into improved OTIF and margin recovery through the year

    Q&A: Analyst Interest

    • Topic: Cause of lower Q1 revenue and whether market demand fell: Management said revenue softness primarily reflected OTIF/shipment timing delays from early-quarter process changes, not decreased product interest. They emphasized continuing excitement for new SPF-infused technologies and expected improved execution through the remainder of 2026.
    • Topic: OTIF texture—supply alignment and SIOP process work: Management clarified that both raw materials and component packaging must arrive on time; they were not consistently aligned at the start of Q1 due to SIOP-related process development. They reported substantial improvements exiting Q1 into Q2 and expected continued OTIF gains.
    • Topic: Meaning of the $47M shipped and open orders number: Management explained it combines orders already shipped within the year as of today plus open orders scheduled for delivery within the year (a type of backlog/guidance). They noted it should be compared with the same-time period last year to assess trajectory.

    Sentiment: MIXED

    Note: This summary was synthesized by AI from the SLSN Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    📋 Official Regulatory 10-K / 10-Q SEC Filings

    Direct authenticated documentation links to audited SEC database reports for SLSN.

    SEC EDGAR Live Feed
    Loading financial data and tables...
    📁

    SEC Filings (SLSN)

    © 2026 Stock Market Info — Solesence, Inc. Common Stock (SLSN) Financial Profile